Catriona Yale - 04 Nov 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Chief Development Officer
Signature: /s/ Jonathan Young, Attorney-in-Fact
Issuer symbol: AKRO
Transactions as of: 04 Nov 2025
Net transactions value: +$199,983
Form type: 4
Filing time: 06 Nov 2025, 07:00:04 UTC
Previous filing: 12 Sep 2025
Next filing: 09 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Yale Catriona	Chief Development Officer	601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO	/s/ Jonathan Young, Attorney-in-Fact	06 Nov 2025	0001779308

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Options Exercise	$99,990	+3,527	+5.3%	$28.35	70,061	04 Nov 2025	Direct
transaction	AKRO	Common Stock	Options Exercise	$99,993	+4,739	+6.8%	$21.10	74,800	04 Nov 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Stock Option (Right to Buy)	Options Exercise	$0	-3,527	-100%	$0.000000	0	04 Nov 2025	Common Stock	3,527	$28.35	Direct	F2
transaction	AKRO	Stock Option (Right to Buy)	Options Exercise	$0	-4,739	-100%	$0.000000	0	04 Nov 2025	Common Stock	4,739	$21.10	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported amount has been adjusted to correct for an overstatement in the Reporting Person's previously reported common stock ownership.
F2	The options are vested and currently exercisable.